{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:51:41Z","timestamp":1792788701072,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.leukres.2017.09.018","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T13:15:26Z","timestamp":1506345326000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma"],"prefix":"10.1016","volume":"62","author":[{"given":"A.","family":"Guidetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mazzocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Paterno\u2019","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Viviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"January (3)","key":"10.1016\/j.leukres.2017.09.018_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"September (27)","key":"10.1016\/j.leukres.2017.09.018_bib0010","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"July (7)","key":"10.1016\/j.leukres.2017.09.018_bib0015","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3109\/10428194.2010.486090","article-title":"Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience","volume":"51","author":"Viviani","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"July","key":"10.1016\/j.leukres.2017.09.018_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0609.2005.00467.x","article-title":"The EORTC strategy in the treatment of Hodgkin's lymphoma","volume":"66","author":"Eghbali","year":"2005","journal-title":"Eur. J. Haematol. Suppl."},{"issue":"August (7)","key":"10.1016\/j.leukres.2017.09.018_bib0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"September (20)","key":"10.1016\/j.leukres.2017.09.018_bib0030","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"27","author":"Eich","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"November (21)","key":"10.1016\/j.leukres.2017.09.018_bib0035","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced hodgkin\u2019s disease. international prognostic factors project on advanced hodgkin\u2019s disease","volume":"19","author":"Hasenclever","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"August (24)","key":"10.1016\/j.leukres.2017.09.018_bib0040","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"April (17)","key":"10.1016\/j.leukres.2017.09.018_bib0045","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"April (12)","key":"10.1016\/j.leukres.2017.09.018_bib0050","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"June (17)","key":"10.1016\/j.leukres.2017.09.018_bib0055","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"June (25)","key":"10.1016\/j.leukres.2017.09.018_bib0060","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"December (24)","key":"10.1016\/j.leukres.2017.09.018_bib0065","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-13-1879","article-title":"Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma","volume":"19","author":"Marri","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"December (12)","key":"10.1016\/j.leukres.2017.09.018_bib0070","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.bbmt.2014.08.016","article-title":"Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma","volume":"20","author":"Farina","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2017.09.018_bib0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/annonc\/13.S1.52","article-title":"Chemokines, cytokines and their receptors in Hodgkin\u2019s lymphoma cell lines and tissues","volume":"13","author":"Maggio","year":"2002","journal-title":"Ann. Oncol."},{"issue":"March (5)","key":"10.1016\/j.leukres.2017.09.018_bib0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.2007.06964.x","article-title":"Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22","volume":"140","author":"Niens","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"July (13)","key":"10.1016\/j.leukres.2017.09.018_bib0085","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1158\/0008-5472.CAN-05-0100","article-title":"Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin\u2019s disease: potential for a prognostic factor","volume":"65","author":"Weihrauch","year":"2005","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.leukres.2017.09.018_bib0090","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3324\/haematol.2011.053199","article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Plattel","year":"2012","journal-title":"Haematologica"},{"issue":"February (2)","key":"10.1016\/j.leukres.2017.09.018_bib0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.23361","article-title":"Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma","volume":"88","author":"Sauer","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"February (3)","key":"10.1016\/j.leukres.2017.09.018_bib0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1078-0432.CCR-12-2693","article-title":"Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma","volume":"19","author":"Jones","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2017.09.018_bib0105","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ. TARC predict PET-Normalization and Event Free Survival in Relapsed\/Refractory Hodgkin Lymphoma patients treated with Brentuximab Vedotin. Blood. 2015, 126 (23): Abstract 180.","DOI":"10.1182\/blood.V126.23.180.180"},{"issue":"August (8)","key":"10.1016\/j.leukres.2017.09.018_bib0110","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-Scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"January (1)","key":"10.1016\/j.leukres.2017.09.018_bib0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/10428194.2013.802784","article-title":"Report on the 4th international workshop on positron emission tomography in lymphoma held in menton, France, 3\u20135 october 2012","volume":"55","author":"Meignan","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"September (27)","key":"10.1016\/j.leukres.2017.09.018_bib0120","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.09.018_bib0125","series-title":"Nonparametric Analysis of Longitudinal Data in Factorial Experiments","author":"Brunner","year":"2002"},{"key":"10.1016\/j.leukres.2017.09.018_bib0130","series-title":"An Introduction to the Bootstrap","author":"Efron","year":"1994"},{"key":"10.1016\/j.leukres.2017.09.018_bib0135","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jclinepi.2004.01.020","article-title":"Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example","volume":"57","author":"Moons","year":"2004","journal-title":"J. Clin. Epidemiol."},{"issue":"January (13)","key":"10.1016\/j.leukres.2017.09.018_bib0140","article-title":"CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma","author":"Cuccaro","year":"2016","journal-title":"Cancer Med."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730526X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261730526X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T02:32:30Z","timestamp":1602988350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261730526X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":28,"alternative-id":["S014521261730526X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.09.018","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}